Journal article

Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance

Joshua WD Tobin, Gabrielle Rule, Katherine Colvin, Lourdes Calvente, David Hodgson, Stephen Bell, Chengetai Dunduru, James Gallo, Erica S Tsang, Xuan Tan, Jonathan Wong, Jessica Pearce, Robert Campbell, Shao Tneh, Sophie Shorten, Melissa Ng, Tara Cochrane, Constantine S Tam, Emad Abro, Eliza Hawkes Show all

Blood Advances | AMER SOC HEMATOLOGY | Published : 2019

Abstract

Management practices in early-stage (I/II) follicular lymphoma (FL) are variable and include radiation (RT), systemic therapy, or combined modality therapy (CMT). There is a paucity of data regarding maintenance rituximab in this cohort. We conducted an international retrospective study of patients with newly diagnosed early-stage FL staged with positron emission tomography (PET)-computed tomography and bone marrow biopsy. Three hundred sixty-five patients (stage I, n = 221), median age 63 years, treated from 2005-2017 were included, with a median follow-up of 45 months. Management included watchful waiting (WW; n = 85) and active treatment (n = 280). The latter consisted of RT alone (n = 17..

View full abstract